Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CSTL 
Castle Biosciences Inc (CSTL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: CSTL (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $36.5
1 Year Target Price $36.5
| 8 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -65.61% | Avg. Invested days 27 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 979.28M USD | Price to earnings Ratio - | 1Y Target Price 36.5 |
Price to earnings Ratio - | 1Y Target Price 36.5 | ||
Volume (30-day avg) 9 | Beta 1.2 | 52 Weeks Range 14.59 - 34.64 | Updated Date 11/6/2025 |
52 Weeks Range 14.59 - 34.64 | Updated Date 11/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.44 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-11-10 | When - | Estimate -0.5544 | Actual -0.02 |
Profitability
Profit Margin -3.56% | Operating Margin (TTM) -8.19% |
Management Effectiveness
Return on Assets (TTM) -1.72% | Return on Equity (TTM) -2.7% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 406276086 | Price to Sales(TTM) 2.85 |
Enterprise Value 406276086 | Price to Sales(TTM) 2.85 | ||
Enterprise Value to Revenue 1.17 | Enterprise Value to EBITDA 12.47 | Shares Outstanding 29188659 | Shares Floating 26928581 |
Shares Outstanding 29188659 | Shares Floating 26928581 | ||
Percent Insiders 2.89 | Percent Institutions 94.21 |
Upturn AI SWOT
Castle Biosciences Inc
Company Overview
History and Background
Castle Biosciences Inc. was founded in 2005. It is focused on providing personalized genomic information to improve healthcare outcomes. Initially focused on melanoma, it has expanded its test offerings to other dermatologic cancers and precision dermatology.
Core Business Areas
- Dermatologic Cancers: Provides diagnostic and prognostic tests for skin cancers, including melanoma, cutaneous squamous cell carcinoma, and basal cell carcinoma.
- Precision Dermatology: Offers tests to personalize treatment approaches for inflammatory skin conditions.
Leadership and Structure
Derek Maetzold is the President and CEO. The company has a typical corporate structure with departments like R&D, Sales & Marketing, Finance, and Operations.
Top Products and Market Share
Key Offerings
- DecisionDx-Melanoma: A gene expression profile test that predicts the risk of metastasis in patients with cutaneous melanoma. There is not publicly available market share data, but is a key product in their dermatology cancer portfolio, generating a significant amount of revenue. Key competitors include Myriad Genetics (MYGN) and Interpace Biosciences (IDXG).
- DecisionDx-SCC: A gene expression profile test for cutaneous squamous cell carcinoma, designed to predict the risk of metastasis. Market share data is not available. Key competitors include Myriad Genetics (MYGN) and Interpace Biosciences (IDXG).
- MyPath Melanoma: A gene expression profile test used to help differentiate between benign nevi and melanoma. Market share data is not available. Key competitors include Myriad Genetics (MYGN) and Interpace Biosciences (IDXG).
Market Dynamics
Industry Overview
The market for dermatologic cancer diagnostics and precision dermatology is growing, driven by increasing incidence of skin cancer and a growing demand for personalized treatment approaches.
Positioning
Castle Biosciences is a leader in the dermatologic cancer diagnostic market, particularly with its gene expression profile tests. Its competitive advantage lies in its proprietary technology and focus on unmet clinical needs.
Total Addressable Market (TAM)
The TAM for skin cancer diagnostics is estimated to be in the billions of dollars. Castle Biosciences is well-positioned to capture a significant share of this market through its established products and pipeline of new tests.
Upturn SWOT Analysis
Strengths
- Proprietary gene expression profiling technology
- Strong clinical evidence supporting test performance
- Experienced management team
- Established sales and marketing infrastructure
- Focus on unmet clinical needs
Weaknesses
- Reliance on reimbursement from payers
- Competition from other diagnostic companies
- Risk of technological obsolescence
- Limited diversification beyond dermatology
Opportunities
- Expansion into new indications
- Development of new diagnostic tests
- Partnerships with pharmaceutical companies
- International expansion
- Increased awareness of personalized medicine
Threats
- Changes in reimbursement policies
- Increased competition
- Negative clinical trial results
- Economic downturn
- Regulatory changes
Competitors and Market Share
Key Competitors
- MYGN
- IDXG
- VRML
Competitive Landscape
Castle Biosciences has a strong position in the dermatologic cancer diagnostic market, but faces competition from larger diagnostic companies like Myriad Genetics. Castle Biosciences' focus on personalized medicine and proprietary technology provide a competitive advantage.
Growth Trajectory and Initiatives
Historical Growth: Castle Biosciences has experienced strong revenue growth in recent years, driven by increased adoption of its diagnostic tests.
Future Projections: Analysts project continued revenue growth for Castle Biosciences, driven by expansion into new markets and development of new products.
Recent Initiatives: Recent initiatives include expanding the sales force, launching new diagnostic tests, and pursuing partnerships with pharmaceutical companies.
Summary
Castle Biosciences is a strong player in the dermatologic cancer diagnostic market, driven by its proprietary gene expression profiling technology and focus on personalized medicine. Its strong clinical evidence and experienced management team provide a solid foundation for future growth. However, the company faces challenges related to reimbursement, competition, and technological obsolescence and needs to keep on top of future acquisitions.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Third-party market research reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is approximate and may vary depending on the source. Financial data requires current data from financial websites and the stock's home page
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Castle Biosciences Inc
Exchange NASDAQ | Headquaters Friendswood, TX, United States | ||
IPO Launch date 2019-07-25 | Founder, CEO, President & Director Mr. Derek J. Maetzold | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 823 | Website https://castlebiosciences.com |
Full time employees 823 | Website https://castlebiosciences.com | ||
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), uveal melanoma, and mental health conditions. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a risk stratification spatial-omics test to predict future development of progression of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide optimal drug treatment for patients diagnosed with major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. The company offers its products to skin cancer and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.